What the research shows about CJC-1295 with and without DAC
CJC-1295 exists as a DAC form and a no-DAC form with opposing effects on the body's natural growth hormone pulsatility, a distinction whose long-term consequences the peptide community has not yet resolved.
I · THE TWO FACES OF ONE PEPTIDE
CJC-1295 is the same 29-amino-acid peptide in both forms, but the presence or absence of the Drug Affinity Complex changes the molecule’s behavior so dramatically that the two versions produce fundamentally different biological signals.
The peptide community has a naming problem that creates real confusion at the point of clinical decision-making, because “CJC-1295” is used interchangeably to refer to two compounds that behave nothing like each other in the body. CJC-1295 with DAC is the original molecule, first synthesized by ConjuChem in the early 2000s, and it carries a Drug Affinity Complex (a reactive maleimide group attached to the lysine side chain) that binds covalently to serum albumin, giving it a terminal half-life of 5.8 to 8.1 days. CJC-1295 without DAC is technically modified GRF 1-29: the first 29 amino acids of growth hormone releasing hormone with four amino acid substitutions that improve stability and eliminate the albumin-binding moiety entirely. The two compounds share a peptide backbone, which is why they share a name, but the DAC turns a 30-minute signal into a week-long one, and that single pharmacokinetic difference reshapes every downstream biological effect. Dr. Alex, who has published extensively on GH secretagogue pharmacology and protocol design, frames the distinction in terms that cut through the nomenclature confusion: the short-acting GHRH analogs (CJC-1295 without DAC, tesamorelin, sermorelin) are physiologic because they increase pulse amplitude while preserving the body’s natural rhythm, whereas the long-acting version (CJC-1295 with DAC) is pharmacologic because it creates a continuous signal the body never produces on its own. 1
When someone in a peptide forum or clinic says “I’m on CJC,” the follow-up that determines everything about their protocol, their risk profile, and their expected outcomes is a simple one: with or without DAC? The answer to that single question splits the entire therapeutic approach into two distinct categories with different dosing schedules, different monitoring requirements, and different theoretical risk profiles.
Walker, another researcher who has contributed significantly to the clinical understanding of GH secretagogues, reinforces this framework with pharmacokinetic data showing that the two versions produce GH profiles that look nothing alike: one preserves the peaks and troughs of natural secretion, the other flattens them into a sustained elevation that never returns to baseline. The practical implication is that choosing between these two compounds represents a decision about whether to amplify a natural signal or replace it with an artificial one, and the downstream consequences of that decision unfold over months and years rather than days.
II · HOW DAC HIJACKS THE HALF-LIFE
The Drug Affinity Complex is a pharmacokinetic mechanism that turns a peptide the kidneys would clear in under an hour into one that circulates for nearly a week, and the biochemistry of how it works is elegant enough to deserve a close look before discussing the biological implications.
The DAC modification operates through a single covalent bond: the maleimide group on the DAC reacts with the free thiol on cysteine-34 of serum albumin, which is the most abundant protein in blood and circulates for roughly three weeks before being degraded by the reticuloendothelial system. Because the covalent bond is stable in circulation and resists hydrolysis, the CJC-1295 molecule remains attached to albumin until the albumin itself is turned over, which means the peptide is released slowly and continuously rather than cleared in a single renal pass. The terminal half-life of 5.8 to 8.1 days, documented in the original ConjuChem pharmacokinetic studies and replicated by independent laboratories, makes CJC-1295 with DAC one of the longest-acting peptide hormones ever developed for therapeutic use, and it is this extraordinary half-life that enables twice-weekly dosing to maintain continuous GH pathway activation. 2
CJC-1295 without DAC clears from circulation in roughly 20 to 50 minutes, which is why it requires nightly subcutaneous administration to maintain a therapeutic effect. CJC-1295 with DAC maintains elevated GH for five to eight days from a single injection, which means a twice-weekly schedule provides continuous coverage. The convenience difference is the primary reason many practitioners and patients gravitate toward the DAC version.
The biological consequence of this sustained release is not subtle, and it reveals itself most clearly when you look at what happens to the GH concentration between pulses. In a healthy young adult, GH pulses roughly every three to four hours with the largest pulse occurring during the first hours of deep sleep, and between pulses GH returns to very low baseline levels, often below the detection limit of standard assays. CJC-1295 with DAC eliminates these troughs almost completely, producing a 7.5-fold elevation in the inter-pulse GH concentration while also increasing pulse amplitude, so the net effect is more total GH exposure across the 24-hour cycle with a fundamentally different temporal pattern. Whether this pattern is desirable depends on whether you believe the trough serves a purpose, and that question leads directly into the pulsatility debate that separates practitioners into two camps.
III · WHY PULSATILITY IS THE WHOLE DEBATE
The GH pulse builds tissue through mTOR and IGF-1, and the trough between pulses repairs it through AMPK and sirtuins, so a molecule that eliminates the trough eliminates the repair period along with it, which means the anabolic benefits everyone can see may come with catabolic costs that accumulate invisibly over time.
Understanding why this matters requires looking at what happens during the GH trough, because the trough is not simply a pause in signaling: it is an active metabolic state with its own distinct biochemistry. During the trough, when GH and IGF-1 levels fall, AMPK activates and triggers autophagy, the cellular recycling program that clears damaged proteins and dysfunctional mitochondria, while sirtuins deacetylate proteins involved in stress resistance and DNA repair. These catabolic and repair processes are essential maintenance mechanisms through which cells prevent the accumulation of the molecular damage that drives aging. López-Otín and colleagues, in their foundational work on the hallmarks of aging published in Cell, established mTOR dysregulation as one of the primary drivers of cellular senescence, and the body’s pulsatile GH release pattern evolved precisely to prevent the continuous mTOR activation that would occur if GH were released steadily throughout the day. 3
mTOR is the accelerator pedal: it tells the cell to grow, divide, and build protein. AMPK is the fuel gauge: it checks whether the cell has the energy and resources to sustain that growth. When mTOR is active and AMPK is suppressed: which is exactly what happens during sustained GH elevation: the cell keeps building without checking the fuel gauge. The GH trough is the moment the cell checks the gauge. A molecule that eliminates the trough eliminates the check.
The concern that Dr. Alex has articulated repeatedly in the peptide medicine community is that continuous mTOR/IGF-1 pathway activation, without the AMPK/sirtuin recovery periods that natural pulsatility provides, could theoretically accelerate aspects of aging even while producing visible anabolic benefits in the short term. This follows directly from the established biology of nutrient-sensing pathways and their role in longevity: caloric restriction extends lifespan across species in large part because it suppresses mTOR and activates AMPK and sirtuins, and continuous GH elevation pushes both pathways in the opposite direction: activating mTOR and suppressing AMPK: around the clock. The practical concern is that CJC-1295 with DAC might produce favorable body composition changes on the outside while doing something less favorable on the inside, and because no long-term human trial has tracked patients on continuous GH secretagogue exposure for more than a few months, nobody can say with confidence whether this tradeoff is real or theoretical.
The fundamental question is whether continuous GH pathway activation is desirable or whether the body’s pulsatile design contains information we should respect rather than override.
Dr. Alex, Peptide Medicine Commentary, 2024
CJC-1295 without DAC sidesteps this entire concern because it increases pulse amplitude while allowing GH to return to baseline between pulses, which means the AMPK/sirtuin recovery window remains intact and the catabolic repair processes still get their turn. Walker’s pharmacokinetic data confirms that modified GRF 1-29 produces a GH profile that is essentially a larger version of the natural pattern rather than a different pattern entirely, and the body’s regulatory architecture: including the negative feedback loop through somatostatin: continues to function normally. This is the physiologic approach, which requires more frequent administration but carries none of the theoretical long-term risk associated with continuous pathway activation. 4
IV · THE PRACTICAL COMPROMISE
The community has not settled the pulsatility question with a definitive clinical trial, which means every practitioner who reaches for CJC-1295 with DAC is navigating a tradeoff between convenience and a theoretical long-term risk that nobody can yet quantify, and the cycling protocols that try to split the difference may not work as well as their proponents hope.
The standard protocol for CJC-1295 with DAC attempts to reintroduce troughs artificially through cycling: five days on and two days off is the most commonly cited schedule, with doses typically ranging from 1 to 2 mg administered twice weekly via subcutaneous injection. Whether two days off actually restores meaningful AMPK/sirtuin activity is unknown and frankly unlikely, because the six- to eight-day half-life means GH remains substantially elevated through the weekend, and the off-period may simply reduce the degree of continuous activation rather than creating a true trough that allows complete pathway recovery. Practitioners who use the DAC version argue that cycling mitigates the concern, but the pharmacokinetics suggest the mitigation is partial at best: better than no cycling but nowhere near the same as preserving natural pulsatility. 5
CJC-1295 without DAC is almost never used alone in practice. The standard stack pairs it with ipamorelin, a GHRP that signals through the ghrelin receptor, at matching doses of 100 to 300 mcg of each compound administered subcutaneously before bed. Ipamorelin amplifies the amplitude of the natural GH pulse without affecting the trough, which makes the combination complementary in the genuine sense: a bigger physiologic signal rather than a pharmacologic override. The nightly administration aligns with the body’s largest natural GH pulse during the first hours of deep sleep, and because ipamorelin is highly selective: it stimulates GH without the cortisol, prolactin, or hunger spikes that other GHRPs can trigger: it has become the preferred GHRP partner in community protocols.
The decision between the two versions ultimately comes down to what you are trying to achieve and what risk profile you are prepared to accept, because the data is clear enough to inform a choice without being complete enough to make the choice for you. For practitioners who prioritize metabolic restoration and view the goal as returning IGF-1 to the upper third of the age-adjusted normal range rather than pushing past it, the no-DAC approach: nightly, stacked with ipamorelin, preserving pulsatility: aligns with everything we know about the biology of aging and the evolutionary design of the somatotropic axis. For practitioners who need compliance simplicity, who are treating patients who will not commit to nightly injections, and who accept the theoretical risk in exchange for the practical certainty of sustained GH elevation and the visible body composition results that come with it, the DAC version has a defensible place in the toolkit. The question is whether you are restoring a signal or overriding one, and the answer to that single question determines which version of the same peptide backbone belongs in your protocol.
- Dr. Alex’s framework distinguishing physiologic from pharmacologic GH secretagogue signaling is drawn from his published clinical commentary and protocol documentation within the peptide medicine community. The classification of short-acting GHRH analogs (CJC-1295 without DAC, tesamorelin, sermorelin) as physiologic and long-acting CJC-1295 with DAC as pharmacologic is a direct articulation of the pulsatility preservation argument.
- The 5.8 to 8.1 day terminal half-life for CJC-1295 with DAC and the mechanism of albumin binding via the maleimide-Cys34 covalent bond are documented in the original pharmacokinetic characterization studies conducted by ConjuChem and have been replicated in subsequent independent laboratory analyses.
- López-Otín, Blasco, Partridge, Serrano, and Kroemer, “The Hallmarks of Aging,” Cell, 153(6), 1194-1217 (2013). This landmark paper establishes mTOR dysregulation as a primary driver of cellular aging and provides the mechanistic foundation for the concern that continuous GH pathway activation may carry long-term costs that short-term anabolic benefits do not reveal.
- Walker’s pharmacokinetic analysis of modified GRF 1-29 (CJC-1295 without DAC) confirms that the compound increases GH pulse amplitude while preserving the natural pulsatile rhythm, including the return to baseline between pulses and the intact negative feedback loop through somatostatin.
- The 5-on/2-off cycling protocol for CJC-1295 with DAC is the most commonly cited schedule in community practice, but no published clinical trial has tested whether this protocol meaningfully restores AMPK/sirtuin activity during the off-period, and the pharmacokinetic half-life of 5.8 to 8.1 days suggests that GH remains substantially elevated throughout the two-day break.